Carfilzomib, which is a proteasome inhibitor under development as a treatment for multiple myeloma, has recently been shown to be a safe and effective treatment for myeloma patients with kidney failure, chromosomal abnormalities, or peripheral neuropathy. These results will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Additionally, ASH presenters will examine the effects of carfilzomib in patients who have previously been treated with Velcade (bortezomib) and in patients who are receiving carfilzomib in combination with…

Preliminary results from several clinical trials testing carfilzomib for the treatment of multiple myeloma will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Carfilzomib, a proteasome inhibitor, is under development as a treatment for relapsed or refractory multiple myeloma. It is currently in Phase 2 of clinical testing, which means that its safety and efficacy are being studied.

The ASH presenters will examine the effects of carfilzomib in patients who have previously been treated with

On Monday, Onyx Pharmaceuticals agreed to purchase Proteolix, the developer of the cancer drug carfilzomib, for $276 million. Carfilzomib, which is Proteolix’s leading cancer drug, has demonstrated significant tumor-reduction activity in Phase 1 trials of patients with relapsed multiple myeloma.

Similar to Velcade (bortezomib), carfilzomib is a proteasome inhibitor that blocks the activity of these protein-destroying enzymes and induces cancer cell death. Carfilzomib is currently undergoing Phase 2 trials on patients with relapsed multiple myeloma, for which data will be reported in late 2010. Phase 3 trials combining carfilzomib…

Preliminary results from an ongoing Phase 1 clinical trial indicate that carfilzomib, a new proteasome inhibitor, has significant therapeutic results in patients with relapsed myeloma. The Multiple Myeloma Research Consortium (MMRC) reported the results at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, which was held in Berlin from September 20 to 24.

Carfilzomib selectively induces cell death in cancer cells by blocking the activity of proteasomes, which are enzymes that break down proteins. Carfilzomib is similar to Velcade (bortezomib), the first proteasome inhibitor approved for multiple myeloma treatment.…

 
Description:
Carfilzomib (news articles, forum discussions), which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many…